2006
Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
1996
Circulating antibodies against p53 protein in patients with ovarian carcinoma
Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis E. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 1996, 78: 2146-2152. PMID: 8918407, DOI: 10.1002/(sici)1097-0142(19961115)78:10<2146::aid-cncr15>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsOvarian carcinomaP53 antibodiesP53 autoantibodiesPositive patientsSuch antibodiesMultivariate analysisPatient disease-free survivalKaplan-Meier survival curvesSerum p53 antibodiesTumor p53 overexpressionDisease-free survivalOlder patient ageSubset of patientsTumor histologic typeOverall patient survivalSera of patientsFrequent molecular eventUnits/LFree survivalNegative patientsOverall survivalPatient ageSuch autoantibodiesAntibody levels
1995
Expression of the prostate-specific antigen gene by a primary ovarian carcinoma.
Yu H, Diamandis E, Levesque M, Asa S, Monne M, Croce C. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Research 1995, 55: 1603-6. PMID: 7536128.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceBlotting, SouthernBudd-Chiari SyndromeChromatography, High Pressure LiquidDNA PrimersDNA, NeoplasmFemaleGene ExpressionGlucocorticoidsHumansImmunohistochemistryLiver TransplantationMiddle AgedMolecular Sequence DataOvarian NeoplasmsPolymerase Chain ReactionProstate-Specific AntigenConceptsProstate-specific antigenPrimary ovarian carcinomasLiver transplantationOvarian tumorsOvarian carcinomaPSA geneProstate-specific antigen geneBreast carcinoma cell linesCarcinoma cell linesPSA cDNAProstate tissueTumor tissueTumorsEpithelial cellsTranscription-PCRWhole coding sequencePatientsTransplantationCarcinomaCell linesImmunohistochemistryAntigen geneTissue culture experimentsTissueDNA sequencingImmunoreactive prostate‐specific antigen in lung tumors
Levesque M, Yu H, D'Costa M, Tadross L, Diamandis E. Immunoreactive prostate‐specific antigen in lung tumors. Journal Of Clinical Laboratory Analysis 1995, 9: 375-379. PMID: 8587005, DOI: 10.1002/jcla.1860090607.Peer-Reviewed Original ResearchConceptsProstate-specific antigenImmunoreactive prostate-specific antigenLung tumor extractsFavorable prognostic indicatorSquamous cell carcinomaSteroid hormone actionMale patientsPrognostic significanceCell carcinomaPrognostic indicatorLung cancerLung tissueBreast cancerLung tumorsPresence of PSAProstate carcinomaTumor extractsBreast tumorsBiochemical markersHormone actionTumorsEpithelial cellsCarcinomaCancerAntigen